Indaptus Therapeutics, Inc. INDP 深 沪
等待开盘 03-27 09:30:00 美东时间
1.81
+0.050
+2.84%
华盛通- 最 高2.015
- 今 开1.71
- 成交量 6059股
- 最 低 1.62
- 昨 收 1.76
- 总市值 1494.81万
- 52周最高 13.40
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.3014
- 委 比 40.51%
- 总股本 825.86万
- 历史最高 784.00
- 量 比 0.31
- 振 幅 22.44%
- 历史最低 0.3014
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Market-Moving News for December 24th
PATH: 8% | UiPath To Replace Synovus Financial In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Friday, January 2; Versant Media Group To Replace Brandywine Realty Trust In The S&P Smallcap
2025-12-24 20:20
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.
2025-12-24 14:56
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading?
Indaptus Therapeutics surged 64.65% in after-hours trading following a major insider investment and board appointment.
2025-12-24 11:12
Indaptus Therapeutics Appoints David Lazar As The Co-Chief Executive Officer
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001857044/000149315225029107/form8-k.htm
2025-12-24 06:34
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. announced the sale of approximately $2.3 million in convertible promissory notes and warrants, as part of a $5 million offering. The notes mature in July 2026, bear 6% interest, and convert into common stock at 80% of the average closing price up to $0.40. Warrants for 200% of conversion shares will follow. Proceeds will fund research, including a Phase 1b/2 trial, and general corporate use.
2025-06-13 12:00
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics begins a new trial arm to study the safety, dosing, and anti-tumor activity of combining Decoy20 with Beigene's PD-1 inhibitor tislelizumab in patients with advanced solid tumors that have not responded to prior checkpoint inhibitors or are typically unresponsive.
2025-06-02 12:00
